How much Sitagliptin effective in control o... - Diabetes India

Diabetes India

61,843 members12,096 posts

How much Sitagliptin effective in control of diabetes?

vipkolon profile image
5 Replies
Written by
vipkolon profile image
vipkolon
To view profiles and participate in discussions please or .
Read more about...
5 Replies
diabeteshealth profile image
diabeteshealth

Anything from 25 mg. to 100 mg. Should be referred by diabetologist .

Vittalanand profile image
Vittalanand

Sitagliptin (Januvia ) is banned and will not be available in markets. But medicine in the same group named VILDAGLIPTIN by names JALRA and GALVUS are available in the strength of 25 and 50 mg. Thisis one tablet once a day type and excess strength or repeat dose in a day will not be effective. Both 25 mg and 50 mg tablets are almost of the same price.

Aggie58 profile image
Aggie58 in reply to Vittalanand

If Sitagliptin is a banned drug in India then how is it available..companies like Sunpharma are sellling it..as istavel100..please advise

vipkolon profile image
vipkolon

Sitagliptin is not banned in India. Glenmark has priced its drugs, Zita and Zita Met, at about 20 to 30 percent cheaper than Januvia and Janumet, monthly dosages of which sell for 1,300 rupees ($24) and 1,900 rupees ($35), respectively. They have been on the Indian market since 2008.

he first DPP-IV inhibitor to enter the market was Sitagliptin marketed as sitagliptin phosphate under the trade name Januvia) introduced in 2006 in the US by Merck, is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2.

Today, Januvia & its combination version Janumet (combined with metformin) dominates sales of DPP-IV products in developed markets, with the brand accounting for about 80% of worldwide sales for single-compound products. Januvia ,a blockbuster drug by Merck & Co. ,is a real success story.

Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year. Glenmark has named its generic medicines Zita and Zita Met and aims to grab a share of $600 million (Rs 3000 crore) in the Indian anti-diabetic market.

Manikb_61 profile image
Manikb_61 in reply to vipkolon

Multination companies claim as their products are highly qualitative and drug concentration in the blood is good. How about Zita quality

You may also like...